在预设的期中分析中，顶线结果显示，与医生选择的化疗方案相比，iza-bren在无进展生存期(PFS)及总 生存期(OS)均获得具有统计学意义和临床意义的显著改善，研究成功达到双重主要终点。 这项研究是iza-bren达到主要终点的第3项III期临床研究。在三阴性乳腺癌中，iza-bren是全球首个在III 期研究中报告PFS和OS双阳性结果的双抗ADC药物。 iza-bren (BL-B01D1)是全球首创(First-in-class)、新概念(New concept)且率先进入唯一进入III期临床试验 阶段的EGFR×HER3双抗ADC。截至2026年1月，百利天恒与战略合作伙伴BMS正在就iza-bren开展40余 项针对多种肿瘤类型的临床试验： 美国华盛顿州雷德蒙德&新泽西州普林斯顿——SystImmune, Inc.(简称"SystImmune")与Bristol Myers Squibb(简称"BMS")共同宣布：SystImmune母公司四川百利天恒药业股份有限公司(简称"百利天恒")公布 了一项III期临床研究(BL-B01D1-307)的预设期中分析取得积极顶线结果。该项研究评估iza- b ...

如果将人类抗击癌症的历史视为一场漫长的战役，那么2014年无疑是这场战役中的"诺曼底登陆"。在此之前，尽管手术、放疗、化疗和靶向药 已经构筑了坚固的防线，但面对晚期癌症的肆虐，人类依然显得防守有余而进攻不足。直到PD-1抑制剂的横空出世，战局被彻底改写。 这一年，百时美施贵宝（BMS）的 欧狄沃（Opdivo，俗称O药）与 默沙东（Merck）的 可瑞达（Keytruda，俗称K药）相继问世。它们不直接 毒杀癌细胞，而是通过解除人体免疫系统的"刹车"，唤醒沉睡的免疫T细胞去围剿肿瘤。这一机制的发现，不仅让詹姆斯·艾利森（James Allison）与本庶佑（Tasuku Honjo）在2018年共同登上了诺贝尔奖的领奖台，更在商业世界掀起了一场持续十年的双雄争霸。 从最初O药的独领风骚，到K药的绝地反击，再到如今K药登顶全球"药王"宝座，这段历史充满了科学的偶然、商业的豪赌与宿命般的逆转。 而当我们站在2026年回望，这场战争并未终结，新的挑战者已然在东方崛起。 一、溯源 1. 免疫治疗的"黑暗中世纪" 直到20世纪末，随着T细胞、树突状细胞等免疫大军被逐一识别，科学家们才重新捡起了这把遗落的钥匙。 故事的起 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - 2025 saw a record high in innovative drug asset transactions among multinational pharmaceutical companies, with 142 cases and a total transaction value of $264.5 billion, marking new highs since 2015 [3][9] - Eli Lilly's revenue for 2025 increased by 44% year-on-year, driven by GLP-1 drugs, with Tirzepatide achieving $36.5 billion in sales [3][39] - Novo Nordisk's sales growth was impacted by increased competition in the weight loss drug market, with a projected revenue decline of 5% to 13% for 2026 [3][40] Summary by Sections 1. Innovative Drug Asset Transactions - In 2025, the number of innovative drug transactions reached 142, with mergers and acquisitions (M&A) and collaborations at 36 and 106 respectively, both setting new records since 2015 [3][9] - The total transaction value was $264.5 billion, with M&A accounting for $106 billion and collaborations for $158.4 billion, also new highs since 2015 [3][9] 2. Performance Review of Pharmaceutical Companies - Eli Lilly's total revenue for 2025 was $65.2 billion, with a guidance for 2026 revenue between $80 billion and $83 billion, indicating a projected growth of 25% [3][39] - Novo Nordisk's total revenue for 2025 was 309.1 billion Danish Kroner, with a guidance for 2026 indicating a decline of 5% to 13% [3][40] - Other companies like AbbVie, AstraZeneca, and Roche reported single-digit growth, while JNJ and Gilead faced challenges due to patent expirations [3] 3. Factors Influencing M&A Decisions - Demand for acquisitions is driven by the need to address revenue gaps from expiring patents and declining R&D efficiency [3][19] - Financial capacity for M&A is supported by free cash flow after shareholder returns, allowing for smaller acquisitions [3][20] - Pricing considerations are crucial, as the valuation of innovative drug assets significantly impacts the internal rate of return (IRR) for acquisitions [3][21]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - 2025 saw a record high in innovative drug asset transactions among multinational pharmaceutical companies, with 142 cases and a total transaction value of $264.5 billion, marking new highs since 2015 [3][9] - Eli Lilly's revenue for 2025 increased by 44% year-on-year, driven by GLP-1 drugs, with Tirzepatide achieving $36.5 billion in sales [3][39] - Novo Nordisk's sales growth was impacted by increased competition in the weight loss drug market, with a projected revenue decline of 5% to 13% for 2026 [3][40] Summary by Sections 1. Innovative Drug Asset Transactions - In 2025, the number of innovative drug transactions reached 142, with mergers and acquisitions (M&A) and collaborations at 36 and 106 respectively, both setting new records since 2015 [3][9] - The total transaction value was $264.5 billion, with M&A accounting for $106 billion and collaborations for $158.4 billion, also new highs since 2015 [3][9] 2. Performance Review of Pharmaceutical Companies - Eli Lilly's total revenue for 2025 was $65.2 billion, with a guidance of $80 billion to $83 billion for 2026, indicating a projected growth of 25% [3][39] - Novo Nordisk's revenue for 2025 was 309.1 billion Danish Krone, with a guidance for 2026 indicating a decline of 5% to 13% [3][40] - Other companies like AbbVie, AstraZeneca, and Roche reported single-digit growth, while JNJ and Gilead faced challenges due to patent expirations [3] 3. Factors Influencing M&A Decisions - Demand for acquisitions is driven by the need to address revenue gaps from expiring patents and declining R&D efficiency [3][19] - Financial capacity for M&A is supported by free cash flow after shareholder returns, allowing for smaller acquisitions [3][20] - Pricing considerations are crucial, as the valuation of innovative drug assets significantly impacts the internal rate of return (IRR) for acquisitions [3][21]

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth On February 25, RBC Capital initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target. The firm said Bristol Myers has “large-cap pharma’s most significant Phase 3 path,” pointing to the depth of its late-stage pipeline. The analyst no ...

5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever - 24/7 Wall St.[S&P 5006,919.80 +0.42%] [Dow Jones49,382.90 +0.44%][Nasdaq 10025,095.40 +0.46%][Russell 20002,672.51 +0.79%][FTSE 10010,783.00 +0.64%][Nikkei 22559,570.30 +2.83%][Stock Market Live February 25, 2026: S&P 500 (SPY) Up on Trump and Tech][Investing]# 5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever### Quick ReadThe Social Security cost-of-living adjustment (COLA) for 2026 was just 2.8%.The COLA for this year worked o ...

Group 1 - The New York Stock Exchange (NYSE) announced that MSCI Emerging Markets Index Options and MSCI EAFE Index Options will begin trading on NYSE Arca Options under the ticker symbols MXEF and MXEA [1] - Canva has acquired MangoAI and Cavalry to enhance its professional creative suite and AI capabilities [1] - Dynatrace's CEO Rick McConnell will announce the company's achievement of surpassing $1 billion in lifetime AWS Sales during an NYSE Live event [1] Group 2 - Equities are reported to be higher as Nvidia prepares to release its fourth quarter earnings after market close [1] - Americares emphasized the importance of increasing access to healthcare in its recent communications [1] - Bristol-Myers Squibb is holding its annual meeting of top 100 global leaders [1]

Investment Rating - The report maintains a "Positive" investment rating for the industry [2]. Core Insights - NLRP3 inflammasome is identified as a significant target for drug development due to its role as a "receiver and converter" of inflammatory signals, indicating substantial therapeutic potential [11][12]. - NLRP3 inhibitors, particularly VTX3232, have shown remarkable anti-inflammatory effects and preliminary validation for reducing cardiovascular (CV) risks [22][28]. - The market potential for targeting NLRP3 is significant, with a potential patient population of approximately 25 million in the cardiovascular anti-inflammatory drug scenario [39]. Summary by Sections 1. NLRP3 Inflammasome: A Major Drug Target - NLRP3 acts as an intracellular sensor detecting various microbial patterns and endogenous danger signals, leading to the assembly and activation of the NLRP3 inflammasome [11]. - The NLRP3 inflammasome is linked to several common diseases, including obesity, diabetes, and cardiovascular diseases, highlighting the market potential for NLRP3-targeted therapies [12]. 2. Efficacy of NLRP3 Inhibitors - VTX3232 demonstrated a rapid and significant reduction in high-sensitivity C-reactive protein (hsCRP) levels, with an 80% reduction within the first week and a sustained effect over 12 weeks [28]. - The safety profile of VTX3232 is comparable to placebo, with adverse events occurring at similar rates across treatment groups [29]. 3. Identifying Next-Generation NLRP3 Inhibitors - BGE-102, a novel NLRP3 inhibitor, has shown promising early-phase data, indicating its potential to lower hsCRP levels significantly in obese participants [65][67]. - The competitive landscape for NLRP3 inhibitors includes several active candidates, with BGE-102 being highlighted for its unique structure and mechanism [54].

Piper Sandler将施贵宝的目标价从66美元上调至75美元，维持"增持"评级。(格隆汇) ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best value stocks to buy now. On February 17, Bristol Myers Squibb announced that the FDA accepted its NDA for iberdomide, which is an investigational treatment for patients with relapsed or refractory multiple myeloma/RRMM. If approved, iberdomide would become the first in a new class of oral medicines known as cereblon E3 ligase modulator agents. The FDA granted the application Priority Review and Breakthrough Therapy Designation, setting a target act ...